Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB announces its latest financial results

UCB announces its latest financial results

23rd October 2009

UCB has reported its financial results for the first nine months of 2009, which, according to the firm, are in line with its previous expectations.

Its revenue declined compared to the same period in 2008, something that UCB attributes to generic competition to Keppra (levetiracetam) in the US.

However, it added, this was partially offset by the strong performance of Keppra in Europe, as the drug continued to show double-digit percentage net sales growth on the continent.

Additionally, the strong growth of Xyzal (levocetirizine) in the US and of Zyrtec (cetirizine) in Japan also boosted its sales.

Roch Doliveux, the chief executive of UCB, stated: “While it is still early in the launch roll-out of our major new products Cimzia, Vimpat and Neupro, we are pleased with trends in prescription uptake.”

In other UCB news, the organisation revealed earlier this month that its rheumatoid arthritis therapy Cimzia (certolizumab pegol) has been approved by the European commission.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.